Loading...
Investigators from the industry-sponsored, phase 3 ZUMA-7 trial previously reported that CD19-targeted chimeric antigen receptor (CAR) T-cell therapy with axicabtagene ciloleucel (axi-cel) showed superior event-free survival compared with standard of care high-dose immunochemotherapy followed by autologous stem cell transplantation (HDT-ASCT) in patients with relapsed/refractory large B-cell lymphoma (LBCL; NEJM JW Oncol Hematol Jan 6 2022 and N Engl J Med 2022; 386:640). The investigators now report a prespecified overall survival (OS) analysis at 5 years.
In brief, 359 adults with progression of LBCL during or within 12 months after first-line immunochemotherapy were randomized to receive either axi-cel or an investigator-selected standard…